#gsk

A major development is taking place in the UK's life-sciences sector as GSK plans a new flagship R&D centre in Cambridge.

The planned facility at Cambridge Biomedical Campus will span around 300,000 square feet and is expected to become home to more than 1,000 GSK scientists. The company has announced a £400 million UK investment connected with the new research centre and related site improvements.

The Cambridge location offers an important advantage: researchers can work alongside leading academic, biomedical, and healthcare organisations. This can encourage collaboration and help connect scientific research with clinical applications.

For students and professionals interested in pharmaceutical research, biotechnology, biomedical science, drug discovery, and healthcare innovation, the development highlights the growing importance of Cambridge as a global life-sciences hub.

The project also demonstrates how major pharmaceutical companies are investing in research infrastructure while seeking to accelerate the development of new medicines.

📖 Read the full GSK Cambridge research campus update: https://thecampusreview.com/news/gsk-cambridge-research-campus/

Il y a des acquisitions qui ressemblent à des paris, et d’autres qui ressemblent à des aveux. Quand un géant pharmaceutique débourse plus de dix milliards de dollars pour racheter une biotech dont le grand public n’a probablement jamais entendu parler, c’est souvent le signe que quelque chose de crucial se joue en coulisses, bien loin des communiqués rassurants des directions. GlaxoSmithKline…

Looking to rent in Calgary?

We’re now leasing brand-new luxury apartments with spacious layouts, beautiful finishes, and top-tier amenities.

#Approves 👾

#GSK 👀

#Exdensur🌸

#A ☀️

#Breakthrough 🍘

#Biologic 🍃

#Asthma 🫧

#Management✨

UK Approves GSK’s Exdensur: A Breakthrough Biologic for Asthma Management

https://amoghavarshaonline.blogspot.com/2025/12/uk-approves-gsks-exdensur-breakthrough.html

SEOUL: South Korea’s Samsung Biologics said ⁠on Monday it is acquiring its first U.S. drug production facility from GSK for $280 million to respond ‌to long-term ‌U.S. market demand. The company’s U.S. unit, Samsung Biologics ‌America, is acquiring a 100% stake in Human Genome Sciences Inc of Rockville, Maryland, the South Korean contract drug manufacturer said in a statement. Samsung Biologics…

Simon Jack,Business editorand Archie Mitchell Watch: GSK boss Dame Emma Walmsley lays out competitions facing the UK The US is the best place for a business to invest, the boss of one of the UK’s biggest pharmaceutical companies has said. Dame Emma Walmsley, chief executive of vaccines and medicines giant GSK, said it will invest $30bn (£23bn) in the US by 2030. It comes as other major drug…

Searching for a beautiful home in Southwest Edmonton with all the conveniences right at your doorstep?

Discover Chappelle Villas Townhomes!